Cipla Limited has issued a clarification regarding USFDA inspectional observations on its supply partner Pharmathen International S.A., following media reports about regulatory concerns at the Greek manufacturing facility.

USFDA Inspection Details

The US Food and Drug Administration conducted an inspection at Pharmathen's manufacturing facility in Rodopi, Greece. The inspection resulted in nine inspectional observations being issued to the company.

Cipla's Business Relationship

Cipla clarified that Pharmathen serves as a supply partner, specifically manufacturing Lanreotide Injection for Cipla USA Inc., which is a wholly owned subsidiary of the company. The clarification was made under Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company received communication from stock exchanges seeking clarification on media reports about the USFDA observations, prompting the formal disclosure.

Company Response and Impact Assessment

Cipla stated it is currently evaluating the impact of the USFDA observations on Pharmathen's facility. The company has committed to keeping stock exchanges informed of any updates that may have material impact, in accordance with applicable regulatory requirements.

The clarification was signed by Company Secretary Rajendra Chopra and filed with BSE Limited, National Stock Exchange of India Limited, and SOCIETE DE LA BOURSE DE Luxembourg, covering all relevant stock exchanges where Cipla securities are listed.

Titan Company shares surged 4.09% to ₹4,280 in afternoon trade on Wednesday, emerging as the top gainer in the Nifty50 index after the jewellery-to-watches conglomerate reported stellar Q3 FY26 results that significantly exceeded analyst expectations. The stock opened at ₹4,225 and touched an intraday high of ₹4,312.10, marking a new 52-week high, with robust trading volumes of 28.06 lakh shares worth ₹1,199.94 crore.

Stock Performance and Market Response

The company's market capitalisation stood at ₹3.79 lakh crore following the strong quarterly performance. The stock's bullish momentum was driven by exceptional growth across all business segments, with the overall consumer business growing 40% year-on-year, substantially beating consensus estimates.

Outstanding Q3 FY26 Financial Performance

Titan's consumer business grew 40% year-on-year in Q3 FY26, substantially beating consensus estimates. The domestic jewellery segment, which accounts for the bulk of revenues, grew 41% year-on-year, well above the 25% growth analysts had projected. This performance was driven primarily by a 65% surge in gold prices and substantial increases in average selling prices, though buyer growth remained flat.

Positive Brokerage Response and Target Price Revisions

Brokerage houses have responded positively to the results with several target price upgrades. Goldman Sachs maintained its 'Buy' rating and raised the target price to ₹4,850, citing sharp revenue acceleration across all segments. Nomura also retained its 'Buy' rating with a target of ₹4,500, terming the performance a "significant beat." However, Citi maintained a 'Neutral' stance with a target of ₹4,125.

Business Expansion and Product Innovation

The company added 56 stores during the quarter, expanding its retail network to 3,433 stores. The international business grew 79% year-on-year, led by strong performance in GCC, Singapore and North America markets. Gold coins sales nearly doubled year-on-year, while studded jewellery grew in the mid-twenties. JM Financial estimates standalone EBITDA and PAT growth of 60% and 64% year-on-year respectively.

Strategic Positioning and Future Outlook

The company launched 'beYon', its lab-grown diamond jewellery brand, during the quarter, demonstrating its commitment to innovation and market expansion. Titan's exceptional performance during the quarter highlights the company's resilience in navigating elevated gold price environment while maintaining strong growth momentum across all business verticals, positioning it well for continued market leadership.